Insights open the door for potential precision immunotherapy innovation targeting novel pathways and patient enrichment strategies with the potential to improve clinical trial success rates TORONTO , April 10, 2024 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) ( Frankfurt : 8TV) a generative AI software leader in clinical trial analytics, announces the presentation of new data... Read More